Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India

Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India

“…In published studies genotype 3 is the commonest genotype in India, accounting for 54%-80% of cases. [135][136][137][138][139][140][141][142][143] Within genotype 3, subtype 3a has been the most frequent in most studies, but a recent report found subtype 3b to be the most prevalent. 144 Studies from northern, eastern and western India have uniformly shown predominance of genotype 3; however, in southern India, both genotype 1 and 3 HCV are prevalent.…”

“…110,145 Genotype 4 HCV has been identified in some cases from southern and western India. 139,141,146 Genotype 6 HCV infection has been reported from eastern and northeastern parts of India. 147,148 In a study of 75 isolates from the northeastern part of India with a predominant tribal population, genotype 4 was reported to be to be the commonest genotype (31%) with genotype 6 accounting for 13.6% of cases.…”

Tackling the Hepatitis C Disease Burden in Punjab, India

“…While genotype 1 predominates in Europe, North America, and Australia, genotype 3 is more prevalent in Asian countries namely India, Pakistan, Bangladesh, etc. 2,3 HCV is known to cause both acute and chronic infection in humans and unlike hepatitis B virus (HBV), 80% of acute HCV infections in adults can lead onto chronic viremia. Of these persons with chronic infection, 30% will develop progressive liver disease culminating in cirrhosis and/or hepatocellular carcinoma (HCC).…”

Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C—A Reappraisal from a Tertiary Care Center in Northern India

“…In most of the studies, genotype 3 was overall more common in Northern, eastern and Western parts of India, but patients from South India are predominantly infected with genotype 1. [11][12][13][14][15] In contrast, most of the studies from USA, Europe and Japan have reported a prevalence rate of 60%-70% of genotype 1b and 1a in patients with CH-C. 16 HCV treatment responses vary with the genotype, with the highest SVR rates observed for genotype 2, 3 (72-80%) and the lowest rates observed for genotypes 1 and 4 (44-50%). 13,[17][18][19] Our study population also showed similar results as genotype 1 (20%) had significantly low SVR as compared to genotype 3/2 (92.0%).…”